학술논문

Role of Actinomyces spp. and related organisms in the development of medication-related osteonecrosis of the jaw (MRONJ): Clinical evidence based on a case series.
Document Type
Academic Journal
Author
Kövér Z; 1Department of Dentistry, Oral and Maxillofacial Surgery, Medical School, University of Pécs, Tüzér u. 1., 7623 Pécs, Hungary.; Bán Á; 1Department of Dentistry, Oral and Maxillofacial Surgery, Medical School, University of Pécs, Tüzér u. 1., 7623 Pécs, Hungary.; Gajdács M; 2Department of Oral Biology and Experimental Dental Research, Faculty of Dentistry, University of Szeged, Tisza Lajos krt. 64-66., 6725, Szeged, Hungary.; Polgár B; 3Department of Medical Microbiology and Immunology, Clinical Center, University of Pécs, Szigeti út 12., 7624, Pécs, Hungary.; Urbán E; 3Department of Medical Microbiology and Immunology, Clinical Center, University of Pécs, Szigeti út 12., 7624, Pécs, Hungary.
Source
Publisher: Akadémiai Kiado Country of Publication: Hungary NLM ID: 101569896 Publication Model: Electronic-Print Cited Medium: Print ISSN: 2062-509X (Print) Linking ISSN: 2062509X NLM ISO Abbreviation: Eur J Microbiol Immunol (Bp) Subsets: PubMed not MEDLINE
Subject
Language
English
ISSN
2062-509X
Abstract
Medication-related osteonecrosis of the jaw (MRONJ) is an increasingly common consequence of antiresorptive treatment, which often leads to the development of necrotic exposed bone surfaces with inflammatory processes affecting the jawbone. Although the development of MRONJ is often associated with the inflammatory response or infections caused by the colonizing members of the oral microbiota, the exact pathogenesis of MRONJ is still not fully understood. In the present paper, we aimed to provide additional, microbiological culture-supported evidence, supporting the "infection hypothesis" that Actinomyces spp. and related organisms may play an important pathogenic role in the development of MRONJ and the resulting bone necrosis. In our case series, all patients presented with similar underlying conditions and anamnestic data, and have received antiresorptive medications (bisphosphonates or a RANK ligand (RANKL) inhibitor) to prevent the occurrence or progression of bone metastases, secondary to prostate cancer. Nevertheless, a few years into antiresorptive drug therapy, varying stages of MRONJ was identified in the mentioned patients. In all three cases, quantitative microbiological culture of the necrotic bone samples yielded a complex microbiota, dominated by Actinomyces and Schaalia spp. with high colony counts. Additionally, our followed-up case series document the treatment of these patients with a combination of surgical intervention and long-term antibiotic therapy, where favourable clinical responses were seen is all cases. If the "infection hypothesis" is valid, it may have significant consequences in the preventative and therapeutic strategies associated with this disease.